“We are very pleased to announce that our search for a new leader in oncology has indentified an individual who will provide a vision for the future of this new division,” said Dr. Michael Grever, chairman of the department of internal medicine at the OSUCCC-James. “Miguel is recognized for his dedication to introducing effective new therapy for patients suffering from cancer.”
A native of the Dominican Republic, Villalona is an internationally-recognized expert in experimental therapeutics and lung cancer. He directs Ohio State’s solid tumors experimental therapeutics program. Beyond his work at OSU, he is a National Cancer Institute (NCI) funded scholar, a member of the NCI investigational drug steering committee and has been involved in several important national scientific committees such as the American Society for Clinical Oncology, American Association for Cancer Research and the National Cancer Institute.
The OSUCCC-James’ medical oncology unit was previously part of the department of internal medicine’s division of hematology and medical oncology. The two sections will each become independent divisions within the department of internal medicine.
“The establishment of two divisions allows each division to focus on and further develop their respective areas, which will help enhance our quality and recruitment initiatives, strengthen collaboration through our multimodality clinics and stimulate the translation of discoveries into clinical trials,” said Dr. Michael Caligiuri, director of the OSUCCC and CEO of The James. “The transformation reflects the tremendous growth opportunities that are developing within the cancer program at The Ohio State University.”
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (http://cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only seven funded programs in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.